Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502878 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL5704713 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL13224565 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL13224526 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL609262 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL502879 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL3471145 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL13746294 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL14677435 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL5704707 | 0.83 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217011-A1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | GLUL, GFPT1, QPCT | SLC7A5 59/4885SLC1A2 6/4885SLC1A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.